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doi:10.1016/j.ejvs.2010.07.028Abstract Background and objective: Zoledronate has been reported to inhibit the prolifera-
tion, adhesion and migration of vascular smooth muscle cells. In the present study, we assessed
whether systemic and local delivery of zoledronate would be sufficient to prevent intimal
hyperplasia.
Methods: Twenty-four male Sprague-Dawley rats were assigned into four groups: non-treated
group, systemic zoledronate-treated group, local collagen-treated group and local zoledro-
nate-treated group. All four groups underwent balloon injury to the right common carotid
artery. The left uninjured carotid arteries of the non-treated group were considered as normal
artery samples. Twenty-one days after arterial injury and treatment, the right and left
common carotid arteries were fixed, sectioned, stained and measured by computer-aided
image analysis.
Results: At 3 weeks, there was a 59% reduction of the intima/media area ratio in the systemic
zoledronate-treated group compared with the non-treated group (P < 0.01). There was an 87%
reduction of the intima/media area ratio in the local zoledronate-treated group compared
with the local collagen-treated group (P < 0.01).
Conclusions: Both systemic and local delivery of zoledronate correspond to a significant reduc-
tion in intimal hyperplasia seen at 3 weeks.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Restenosis due to intimal hyperplasia remains the major
obstacle to satisfactory long-term patency of open- and
catheter-based treatment of obstructive arterial disease.
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ty for Vascular Surgery. Publishemuscle cell proliferation and migration are thought to be
central to the development of intimal hyperplasia.1,2 Many
pharmacological agents, including anti-thrombotics, anti-
platelet agents and angiotensin-converting enzyme inhibi-
tors have been used in an attempt to attenuate this injury
response.3
Bisphosphonates, which have been used widely in the
treatment of excessive bone resorption diseases, are stable
analogues of inorganic pyrophosphate. Their half-life in the
circulation is short; they enter rapidly and extensively into
bone, and then inactivate osteoclasts, which regulate boned by Elsevier Ltd. All rights reserved.
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markedly in the aortas of both healthy and atherosclerotic
rabbits in vivo and in human internal mammary arteries in
vitro.5,6 An increasing number of studies have shown that
bisphosphonates could inhibit the development of experi-
mental atherosclerosis and neo-intimal hyperplasia.7,8
These effects were mostly attributed to the transient
systemic inactivation of monocytes and macrophages.
Zoledronate or zoledronic acid is a member of the
newest generation of bisphosphonates and is suggested to
be the most potent bisphosphonate tested to date.9 We
recently reported that zoledronate could exert direct
inhibition on the proliferation, adhesion and migration of
vascular smooth muscle cells without obvious induction of
necrosis or apoptosis. The inhibition was more dramatic
when the concentration reached 10e100 mM.10
The aim of the present study was to investigate whether
systemic and local delivery of zoledronate would be suffi-
cient to prevent intimal hyperplasia.Materials and Methods
Materials
Zoledronate was kindly provided by Novartis Pharma AG
(Stein, Switzerland). Rat tail tendon collagen type I
(5 mg ml1) in 0.006 N acetic acid was purchased from Shen-
gyou Biotechnology Co., Ltd. (Hangzhou, China). The mono-
clonal anti-proliferating cell nuclear antigen (PCNA) antibody
was purchased from Cell Signaling Technology (Danvers, MA,
USA). All other chemicals and reagents were obtained from
commercial sources and were of analytical grade.
Animals
Sprague-Dawley rats (male, 300e350 g) were purchased
from Shanghai Laboratory Animal Centre of Chinese
Academy of Sciences. Animals were fed a standard diet and
water ad libitum. The animals used in this study were
treated in accordance with Health Guide for the Care and
Use of Laboratory Animals and the guidelines of Fudan
University on the ethical use of animals.
Rat balloon-injury model
Balloon injury of the right common carotid arterial endothe-
lium was performed in 24 male Sprague-Dawley rats as
described before.11 Briefly, rats were anaesthetised with 10%
chloral hydrate (3 ml kg1, i.p.). A midline incision was made
in the neck, and the right common carotid artery was
exposed. A small cut was then made in the external carotid
artery, and an embolectomy catheter (Fogarty 2F, Edwards
Laboratories)was passed into thecommoncarotid artery. The
balloonwas inflatedwithwateruntil slight resistancewasmet
to expand the common carotid artery and then slowly twisted
back to the carotid bifurcation. This procedure was done
three times to achieve complete denudation of the endo-
thelium, including a mild-to-moderate injury of the inner
layers of the media smooth muscle cells. Afterwards, the
balloonwas removed, and theexternal carotid artery ligated.Preparation of zoledronate
A stock solution (10 mM) of zoledronate was prepared in
calcium-free phosphate buffered saline. For every 1 ml of
collagen (4.9 mg ml1) and zoledronate (100 mM) mixture,
mix 980 ml of 5 mg ml1 collagen, 10 ml of 10 mM zoledro-
nate and 6 ml of 1 N NaOH. Leave the mixture on ice until
ready for use.
Therapy
The 24 rats were assigned into four groups: non-treated
group (group I), systemic zoledronate-treated group (group
II), local collagen-treated group (group III) and local zoledr-
onate-treated group (group IV). Groups I and III served as
a control for groups II and IV, respectively. All four groups
underwent balloon injury on the right carotid artery. The left
uninjured carotid arteries from group I were considered as
normal artery samples. For the systemic zoledronate-
treated group, a dose of zoledronate (0.05 mg kg1) was
injected, approximating a clinical dose, through the rat tail
vein immediately after the procedure; two more doses were
injected at day 7 and day 14 post procedure. For the local
collagen-treated group, 200 ml of rat tail collagen
(4.9 mg ml1) was coated around the adventitia of the
injured carotid artery right after external carotid ligation.
For the local zoledronate-treated group, 200 ml of rat tail
collagen (4.9mgml1) and zoledronate (100 mM)mixturewas
coated around the adventitia of the injured carotid artery.
Tissue harvest and histology processing
Twenty-one days after arterial injury, rats were anaes-
thetised with 10% chloral hydrate (3 ml kg1, i.p.). The
right (injured) and left (uninjured) segments of the
common carotid arteries were removed and fixed in 10%
buffered formalin. A total of 24 h post fixation, the arterial
segments were dehydrated and embedded in paraffin, and
cut into 6-mm longitudinal sections. Standard haematox-
ylineeosin staining was performed on serial sections.
Morphometry
Thecross-sectionalmedial and intimalareasof the six sections
from the midportion of each tissue segment were measured
with Image-Pro Plus 6.0 image analysis software. Briefly, the
luminal, internal elastic lamina and external elastic lamina
areas were manually measured, the intimal area was calcu-
lated as the internal elastic lamina area minus luminal area
and the medial area was calculated as the external elastic
lamina area minus internal elastic lamina area. The ratio of
the intima to media area was then calculated.
These measurements were performed by one analyst,
who was blinded to the treatment.
Immunohistochemistry of PCNA expression
Immunohistochemical staining was performed on three
sections from the midportion of each tissue segment as
described before.12 Briefly, arterial sections were incubated
with0.3%hydrogenperoxide toblockendogenousperoxidase,
Figure 1 Haematoxylin and eosin stained photomicrographs of rat right carotid artery sections 21 days after balloon injury at
100 magnification. The scale bar represents 100 mm (a) shows representative artery from group I; (b) shows artery from group II;
(c) shows artery from group III; (d) shows artery from group IV.
Figure 2 The medial area of the right carotid artery from all
four groups and the left uninjured arteries from group I. The
area is calculated as mm2. Data are expressed as mean  SEM.
*P < 0.05 compared with left uninjured arteries from group I.
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The percentage of stained nuclei was determined as a ratio of
stained nuclei to the total number of nuclei per high-power
field in the sectionused for analysis. Themeanvalues of these
three sectionswerecalculated foreachvessel. Foreachgroup
of animals, the mean values for each vessel were averaged.
These examinations were performed by one analyst, whowas
blinded to the treatment.
Statistical analysis
Data were mean  standard error of the mean (SEM).
Statistical significance was determined by one-way analysis
of variance (ANOVA) followed by the Bonferroni’s post hoc
test and values of P < 0.05 were considered statistically
significant. All statistical analyses were performed using
GraphPad Prism version 5.0 (San Diego, CA, USA).
Results
Histopathological changes
All the 24 rats were alive and well before sacrifice, and no
major adverse effects were observed in any of the four
groups. Redness and swelling at the infusion site of the rat
tail were observed in group II. Incisions on the neck
generally healed well in group IV.
The entire length of right (injured) and left (uninjured)
common carotid arteries were obtained from the rats 3weeks after balloon injury. Sections from the middle
portion of specimens were analysed. Among the left unin-
jured arteries from group I, the luminal surface was
smooth, the vascular wall only composed of a few layers of
cells and the lumen area was enough for blood flow (data
not shown). As for both the control vessels (groups I and III),
large amounts of cells were present in the subendothelial
space, the lumen area was reduced and the intimal area
increased. Systemic and local delivery of zoledronate
(groups II and IV) was found to improve the above histo-
pathological changes and decrease the extent of neo-
intima (Fig. 1).
Figure 4 Intima/Media ratio 21 days after balloon injury of
all four groups. **P < 0.01 compared with control group.
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The average area of the left uninjured arteries was
0.096 mm2, and all four groups demonstrated an increased
medial area 3 weeks after balloon injury, with an average
area of 0.139 mm2, 0.150 mm2, 0.152 mm2 and 0.135 mm2,
respectively. However, no difference in medial area was
observed between any of the four groups (Fig. 2).
Both control groups (groups I and III) developed a signi-
ficant neo-intima 21 days after balloon injury, with an
average area of 0.271 mm2 and 0.278 mm2, respectively.
Both the systemic and local zoledronate-treated groups
(groups II and IV) were found to have a less neo-intimal
area, with an average area of 0.117 mm2 and 0.034 mm2,
respectively (Fig. 3). Consequently, the intima/media area
ratio was significantly decreased in groups II and IV
compared with those in groups I and III, with a reduction by
59% and 87%, respectively (Fig. 4). No significant difference
was found when the systemic zoledronate-treated group
and the local zoledronate-treated group were compared.
PCNA expression
We also examined the degree of proliferation in neo-intima
as assayed by immunostaining for PCNA. The dark-brown-
labelled PCNA-positive nuclei were observed within the
vascular neo-intima. PCNA is significantly less expressed in
groups II and IV compared with groups I and III (Fig. 5). The
PCNA-positive indices in the four groups were 38.73  5.54,
23.14  6.95, 40.89  3.52 and 14.05  8.64%, respectively
(Fig. 6). Thus, zoledronate was associated with the reduc-
tion of the PCNA-positive indices in neo-intima, consistent
with histopathological changes in neo-intima (P < 0.01).
Discussion
Balloon injury of the common carotid artery is a widely
accepted animal model of intimal hyperplasia. The time
course of neo-intimal growth following balloon injury has
been established; vascular smooth muscle cells in the
media begin to proliferate as they migrate to the intima.
They continue to proliferate for 7e14 days to form an
intimal thickening before stopping spontaneously.1315 InFigure 3 The intimal area of the right carotid artery of all
four groups. The area is calculated as mm2. Data are expressed
as mean  SEM. **P < 0.01 compared with control group.the current study, the rats were sacrificed at 3 weeks in the
light of previous studies.
Many pharmacological agents have been used in an
attempt to attenuate intimal hyperplasia. Bisphospho-
nates, besides extensive application in bone-related
diseases, have been found to exhibit the effects of inhib-
iting development of atherosclerosis and intimal hyper-
plasia by transient systemic inactivation of monocytes and
macrophages.7,8 As bisphosphonates can concentrate in the
arterial wall of both healthy and, especially, atheromatous
rabbits for at least several days or a week,5 we hypoth-
esised that they might exert direct effects on the vascular
smooth muscle cell, which is a major cell type in arterial
wall. In our previous publication, we reported that
zoledronate, a third generation of nitrogen-containing
bisphosphonates, could inhibit the proliferation, adhesion
and migration of vascular smooth muscle cells. The inhibi-
tion was more dramatic when the concentration reached up
to 10e100 mM.
Zoledronate is the most potent bisphosphonate in clin-
ical use. It is known to inhibit cell signalling through the
mevalonate pathway and block the prenylation of small
signalling proteins (e.g., Ras, Rac, Rab and Rho).16 Loss ofFigure 5 PCNA protein expression 21 days after balloon
injury at 400 magnification. Positive expression was detected
by immunohistochemistry (cells stained in dark brown). The
scale bar represents 50 mm (a) shows representative artery
from group I; (b) shows artery from group II; (c) shows artery
from group III; (d) shows artery from group IV.
Figure 6 Effect of systemic and local delivery of zoledronate on the PCNA expression in neo-intima 21 days after balloon injury.
**P < 0.01, compared with control group.
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acting at the correct spatial location within the cell, thus
ultimately affecting their normal behaviour, including cell
proliferation, survival, cytoskeletal organisation and
vesicular trafficking.17
A peak serum concentration of zoledronate following
administration of a clinical dose (4 mg over 15 min) ranges
from 1 to 10 mM.18 It has been suggested, however, that the
effective local concentrations of bisphosphonates at the
sites of artery, especially atherosclerotic artery, may be
much higher than serum levels.5 In our present study, we
injected 0.05 mg kg1 zoledronate once a week, approxi-
mately a clinical dose, to evaluate its effect on intimal
hyperplasia.
As a potential method for the prevention of intimal
hyperplasia, periadventitial administration of pharmaco-
logical agents directly to the injured site in the vascular has
been attracting great interest.1921 Periadventitial delivery
may have the potential advantages of allowing a high
concentration of the agent to be accumulated at the site of
injured artery while minimising the likelihood of systemic
side effects. Collagen is a major natural constituent of
connective tissue and a major structural protein of any
organ. It has long been used as a local drug delivery
material, and its usefulness and safety have been veri-
fied.22 Therefore, in our present study, we periadventitially
applied a high concentration (100 mM) of zoledronate mixed
with collagen on an injured artery to evaluate its effects on
intimal hyperplasia.
Our study shows that neo-intimal area was reduced in
both the systemic and local zoledronate-treated groupscompared with the related control group. However, no
statistical difference, which may be due to small sample
size, in the medial area was observed between any of the
four groups. Consequently, the intima/media area ratio of
the systemic and the local zoledronate-treated group was
significantly decreased compared with the related control
group, by 59% and 87%, respectively. No statistical differ-
ence, which again may be due to small sample size, was
found when the systemic zoledronate-treated group and
the local zoledronate-treated group were compared. The
degree of proliferation in the neo-intima was assayed by
immunostaining for PCNA; it was significantly less expressed
in the zoledronate-treated groups as compared with the
related control groups, consistent with histopathological
changes in neo-intima.
As bisphosphonates have also been reported to concen-
trate in adventitia,6 is the effect of zoledronate on intimal
hyperplasia due to direct inhibition on fibroblasts, which also
play an important role in the development of intimal
hyperplasia?23 Zoledronate has been demonstrated to inhibit
endothelial cell adhesion, migration and survival;24 will
zoledronate delay the process of re-endothelialisation after
injury, which is beneficial to the inhibition of neo-intimal
formation?25 Further research is necessary to optimise
zoledronate to reduce intimal hyperplasia and elucidate the
mechanisms in the balloon-injury model and other different
models. Our promising findings of the efficacy of zoledronate
at reducing intimal hyperplasia are limited to a time frame
of 3 weeks. Long-term observations and optimised drug
carriers are necessary before possible application to
humans.
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